Skip to content

Exploitation of Antibiotic Resistance as a Novel Drug Target: Development of a β-Lactamase-Activated Antibacterial Prodrug

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)4411-4425
Number of pages15
JournalJournal of Medicinal Chemistry
Issue number9
Early online date22 Apr 2019
DateAccepted/In press - 22 Apr 2019
DateE-pub ahead of print - 22 Apr 2019
DatePublished (current) - 9 May 2019


Expression of β-lactamase is the single most prevalent determinant of antibiotic resistance, rendering bacteria resistant to β-lactam antibiotics. In this article, we describe the development of an antibiotic prodrug that combines ciprofloxacin with a β-lactamase-cleavable motif. The prodrug is only bactericidal after activation by β-lactamase. Bactericidal activity comparable to ciprofloxacin is demonstrated against clinically relevant E. coli isolates expressing diverse β-lactamases; bactericidal activity was not observed in strains without β-lactamase. These findings demonstrate that it is possible to exploit antibiotic resistance to selectively target β-lactamase-producing bacteria using our prodrug approach, without adversely affecting bacteria that do not produce β-lactamase. This paves the way for selective targeting of drug-resistant pathogens without disrupting or selecting for resistance within the microbiota, reducing the rate of secondary infections and subsequent antibiotic use.

Download statistics

No data available



  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via ACS at . Please refer to any applicable terms of use of the publisher.

    Final published version, 3.28 MB, PDF document

    Licence: CC BY


View research connections

Related faculties, schools or groups